


INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31830C
APPLICATION NO.
09/884715
APPLICANT
Malcolm Richard Boyd
FILING DATE
JUNE 19, 2001Group
1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	S.A. Bishop et al., Archives of Virology, "Herpes simplex virus infection and damage in the central nervous system: immunomodulation with adjuvant, cyclophosphamide and cyclosporin A", Vol. 116, pp. 57-68 (1991)
AS	D.M. Altmann et al., Clin. Exp. Immunol., "The effects of cyclosporine A on the induction expression and regulation of the immune response to Herpes simplex virus", Vol. 59, pp. 17-22 (1985)
AT	A. Vahine et al., Archives of Virology, "Inhibition of herpes simplex virus production in vitro by Cyclosporin A", Vol. 122, pp. 61-75 (1995)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31830C
APPLICATION NO.
09/884715
APPLICANT
Malcolm Richard Boyd
FILING DATE
JUNE 19, 2001Group
1648EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	J.K. Preiksaitis et al., J. Infect. Dis., "Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy", Vol. 147(6), pp. 974-981 (1983).
DB	C. Berkowitz-Balshayi et al., in-vivo, "Immunosuppression of mice by cyclophosphamide (CyP) and cyclosporine A (CsA) changes the course of HSV-1 infection and the distribution of viral DNA in target organs," Vol. 9, pp. 155-162 (1995).
DC	"Martindale, the complete drug reference" 32 nd edition, editor K. Parfitt, Pharmaceutical Press, pp. 602-606, (antivirals – acyclovir), and p. 624 ("antivirals – penciclovir").
DD	FAMVIR (famciclovir, from Novartis), UK Summary of Product Characteristics, pp. 1-9, January 7, 2005.
DE	Cyclophosphamide 50mg tablets (from Pharmacia Limited), UK Summary of Product Characteristics, pp. 1-6, September 4, 2007.
DF	NEORAL soft gelatine capsules, NEORAL oral solution (ciclosporin, also known as ciclosporin A, from Novartis), UK Summary of Product Characteristics, pp. 1-18, February 9, 2005.
DG	SANDIMMUN concentrate for infusion (ciclosporin 50 mg in 1 ml, concentrate for iv infusion, from Novartis), UK summary of Product Characteristics, pp. 1-9, January 27, 2005.
DH	Copy of current packaging and pack insert for penciclovir (PCV) topical cream (trademark VECTAVIR) for treatment of cold sores, as sent to the present writer in February 2005, and thought to have been bought over-the-counter in either Netherlands or Germany.
DI	Copy of current packaging and pack insert for aciclovir (ACV) topical cream (trademark ZOVIRAX) for treatment of cold sores, as sold by GSK / GW IN THE United Kingdom. The shown package was bought over-the counter (OTC) from a UK pharmacist in July 2004. GSK's aciclovir topical cream is sold Rx (i.e. by prescription) and/or OTC throughout Europe, including Germany and Netherlands.
DJ	Physician's desk reference (PDR) entry for famciclovir (FCV) tablets (trademark FAMVIR), downloaded on November 11, 2004 (February 2002 version).
DK	Physician's desk reference (PDR) entry for valaciclovir hydrochloride orally-administrable caplets (trademark VALTREX), downloaded on November 11, 2004 (May 2003 version),
DL	September 1, 2000 extract from Scrip entitled "SmithKline Beecham sells drugs to Roche and Novartis".
DM	December 14, 2000 extract from Scrip entitled "GlaxoSmithKline to complete in two weeks.
DN	January 2, 2001 extract from Prous Daily Essentials entitled "Antivirals drugs acquired by Novartis from SB".

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31830C
APPLICATION NO.
09/884715
APPLICANT
Malcolm Richard Boyd
FILING DATE
JUNE 19, 2001

Group
1648

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	January 2, 2001 extract from Scrip entitled "GlaxoSmithKline is finally born".
	DB	
	DC	
	DD	
	DE	
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.